{
    "nct_id": "NCT05913713",
    "official_title": "High Intensity Interval Training: Optimizing Exercise Therapy to Mitigate Cardiovascular Disease Risk Following Breast Cancer Chemotherapy",
    "inclusion_criteria": "* female patients based on biological sex\n* 18 to 85 years of age\n* diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer\n* completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation\n* absence of contraindications to exercise or to participate in study\n* study clinician approval\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "* do not meet inclusion criteria\n* scheduled to receive surgery or radiation therapy during the intervention period\n* any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)\n* lymphedema stage â‰¥2 prior to study enrollment\n* are pregnant\n* current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)",
    "miscellaneous_criteria": ""
}